Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Preference study of testosterone undecanoate injection versus testosterone implant pellets in male hypogonadism
ACTRN12606000315516Phase 4Recruiting
- Sponsor
- Schering AG
- Start
- Jul 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 4, randomised, open-label trial of testosterone undecanoate and testosterone in Hypoandrogenism (TD) and androgen deficiency (2 arms), sponsored by Schering AG. Primary endpoint: Individual and disease specific quality of life variables. Started Jul 2006; status: recruiting.
02
Drugs
testosterone undecanoatetestosterone
03
Conditions
Hypoandrogenism (TD)androgen deficiency
Beyond the preview
Go deeper on ACTRN12606000315516.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12606000315516.